ValuEngine Lowers TG Therapeutics (NASDAQ:TGTX) to Hold

TG Therapeutics (NASDAQ:TGTX) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Monday, ValuEngine reports.

A number of other research analysts have also commented on the stock. BidaskClub upgraded shares of TG Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday. Zacks Investment Research upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. TG Therapeutics presently has a consensus rating of “Hold” and an average target price of $11.90.

TGTX traded up $0.06 on Monday, reaching $5.52. The company had a trading volume of 857,443 shares, compared to its average volume of 1,627,330. TG Therapeutics has a fifty-two week low of $3.32 and a fifty-two week high of $9.38. The company’s fifty day moving average is $5.82 and its 200 day moving average is $7.05. The company has a quick ratio of 1.69, a current ratio of 1.69 and a debt-to-equity ratio of 2.77.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.01. TG Therapeutics had a negative net margin of 99,488.13% and a negative return on equity of 496.99%. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. On average, analysts forecast that TG Therapeutics will post -1.54 earnings per share for the current year.

Large investors have recently made changes to their positions in the business. UBS Asset Management Americas Inc. grew its position in shares of TG Therapeutics by 2.5% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 609,374 shares of the biopharmaceutical company’s stock worth $5,271,000 after purchasing an additional 14,975 shares in the last quarter. Swiss National Bank grew its position in shares of TG Therapeutics by 19.9% during the 2nd quarter. Swiss National Bank now owns 140,500 shares of the biopharmaceutical company’s stock worth $1,215,000 after purchasing an additional 23,300 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of TG Therapeutics by 12.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 258,296 shares of the biopharmaceutical company’s stock worth $2,061,000 after purchasing an additional 29,098 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of TG Therapeutics by 10.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 311,004 shares of the biopharmaceutical company’s stock worth $2,690,000 after purchasing an additional 29,627 shares in the last quarter. Finally, Athanor Capital LP acquired a new position in shares of TG Therapeutics during the 2nd quarter worth approximately $198,000. Hedge funds and other institutional investors own 52.99% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Further Reading: What is the return on assets (ROA) ratio?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.